Potassium Channel Kv1.3 Is Highly Expressed by Microglia in Human Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Recent genetic studies suggest a central role for innate immunity in Alzheimer's disease (AD) pathogenesis, wherein microglia orchestrate neuroinflammation. Kv1.3, a voltage-gated potassium channel of therapeutic relevance in autoimmunity, is upregulated by activated microglia and mediates amyloid-mediated microglial priming and reactive oxygen species production in vitro. We hypothesized that Kv1.3 channel expression is increased in human AD brain tissue. In a blinded postmortem immunohistochemical semi-quantitative analysis performed on ten AD patients and ten non-disease controls, we observed a significantly higher Kv1.3 staining intensity (p = 0.03) and Kv1.3-positive cell density (p = 0.03) in the frontal cortex of AD brains, compared to controls. This paralleled an increased number of Iba1-positive microglia in AD brains. Kv1.3-positive cells had microglial morphology and were associated with amyloid-β plaques. In immunofluorescence studies, Kv1.3 channels co-localized primarily with Iba1 but not with astrocyte marker GFAP, confirming that elevated Kv1.3 expression is limited to microglia. Higher Kv1.3 expression in AD brains was also confirmed by western blot analysis. Our findings support that Kv1.3 channels are biologically relevant and microglia-specific targets in human AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Kv1.3 channels were also highly upregulated by CD11b+CD45high CNS immune cells in the 5xFAD brain, consistent with previous findings of increased Kv1.3 expression in microglia in human AD [48].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“Higher Iba1 was noted in the AD frontal cortex in four studies,20, 63, 64, 68 but was the same as control in three others32, 70, 74 and lower in the white matter of the frontal lobe in one study.32”
From Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review (2018) · cites this paper as [63]
In the citing paper
“and are highly expressed by microglia surrounding Aβ plaques in AD [48].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“The central role of microglia in AD pathogenesis is further supported by genetic studies that identified an AD susceptibility locus in CD33, and an increased risk of AD associated with allelic variants in Triggering Receptor Expressed on Myeloid cells-2 (TREM2), both microglial proteins [4–6].”
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“[15] confers an increased risk for late-onset AD [4].”
BackgroundSelf-citationMicroglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“It is suggested that early microglial activation in AD has a neuroprotective effect by promoting clearance of amyloid-β (Aβ, however, in the later stages pro-inflammatory cytokines produced by activated microglia have detrimental effects that promote neurodegeneration [3].”
BackgroundA Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108
Microglial cell origin and phenotypes in health and disease
Saijo, K., & Glass, C. K. (2011) · Nature Reviews Immunology · doi:10.1038/nri3086 · Cited by 1,100 · cited 3×
“The mechanisms underlying microglial polarity (pro-inflammatory M1 or anti-inflammatory or neuroprotective M2) are being defined and it is possible that altered expression of potassium channels could characterize these microglial states [17, 33].”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain
Colton, C. A. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9164-4 · Cited by 877
Grissmer, S., Nguyen, A. N., Aiyar, J., Hanson, D. C., Mather, R. J., Gutman, G. A., Karmilowicz, M. J., Auperin, D. D., & Chandy, K. G. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10594-4 · Cited by 777
The functional network of ion channels in T lymphocytes
Cahalan, M. D., & Chandy, K. G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00816.x · Cited by 599
Lehnardt, S. (2010) · Glia · doi:10.1002/glia.20928 · Cited by 597
Gutman, G. A., Chandy, K. G., Adelman, J. P., Aiyar, J., Bayliss, D. A., Clapham, D. E., Covarriubias, M., Desir, G. V., Furuichi, K., Ganetzky, B., et al. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.9 · Cited by 583
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570 · cited 2×
“The central role of microglia in AD pathogenesis is further supported by genetic studies that identified an AD susceptibility locus in CD33, and an increased risk of AD associated with allelic variants in Triggering Receptor Expressed on Myeloid cells-2 (TREM2), both microglial proteins [4–6].”
BackgroundKv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605136103 · Cited by 538
Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia
Grathwohl, S. A., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2432 · Cited by 401
Varnum, M. M., & Ikezu, T. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0181-2 · Cited by 394
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
Goodman, A. D., Brown, T. R., Edwards, K. R., Krupp, L. B., Schapiro, R. T., Cohen, R., Marinucci, L. N., Blight, A. R., & on behalf of the MSF204 Investigators (2010) · Annals of Neurology · doi:10.1002/ana.22240 · Cited by 374
Veh, R. W., Lichtinghagen, R., Sewing, S., Wunder, F., Grumbach, I. M., & Pongs, O. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00641.x · Cited by 328
Maezawa, I., Zimin, P. I., Wulff, H., & Jin, L.-W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135244 · Cited by 278
Self-citationKaushal, V., Koeberle, P. D., Wang, Y., & Schlichter, L. C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3593-06.2007 · Cited by 238
Microglia Kv1.3 Channels Contribute to Their Ability to Kill Neurons
Fordyce, C. B., Jagasia, R., Zhu, X., & Schlichter, L. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1251-05.2005 · Cited by 213 · cited 1×
“3 channels also control microglial proliferation, oxidative burst and neuronal killing [7, 27, 28].”
BackgroundMatheu, M. P., Beeton, C., Garcia, A., Chi, V., Rangaraju, S., Safrina, O., Monaghan, K., Uemura, M. I., Li, D., Pal, S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.07.015 · Cited by 196
Self-citationWulff, H., Knaus, H.-G., Pennington, M., & Chandy, K. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.776 · Cited by 194
Rus, H., Pardo, C. A., Hu, L., Darrah, E., Cudrici, C., Niculescu, T., Niculescu, F., Mullen, K. M., Allie, R., Guo, L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501770102 · Cited by 184
K+ channels and the microglial respiratory burst
Khanna, R., Roy, L., Zhu, X., & Schlichter, L. C. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.4.c796 · Cited by 182
Fadool, D. A., Tucker, K., Perkins, R., Fasciani, G., Thompson, R. N., Parsons, A. D., Overton, J. M., Koni, P. A., Flavell, R. A., & Kaczmarek, L. K. (2004) · Neuron · doi:10.1016/s0896-6273(03)00844-4 · Cited by 178
A Kv1.5 to Kv1.3 Switch in Endogenous Hippocampal Microglia and a Role in Proliferation
Kotecha, S. A., & Schlichter, L. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-24-10680.1999 · Cited by 155
Guntern, R., Bouras, C., Hof, P. R., & Vallet, P. G. (1992) · Cellular and Molecular Life Sciences · doi:10.1007/bf01923594 · Cited by 147
Engineering a Stable and Selective Peptide Blocker of the Kv1.3 Channel in T Lymphocytes
Pennington, M. W., Beeton, C., Galea, C. A., Smith, B. J., Chi, V., Monaghan, K. P., Garcia, A., Rangaraju, S., Giuffrida, A., Plank, D. W., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052704 · Cited by 138
Self-citationJiang, T., Yu, J., Zhu, X., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8424-8 · Cited by 131
Schilling, T., & Eder, C. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22675 · Cited by 117
Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
D. Skaper, S. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794488638 · Cited by 113
Kv1.3 potassium channels as a therapeutic target in multiple sclerosis
Rangaraju, S., Chi, V., Pennington, M. W., & Chandy, K. G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903018957 · Cited by 99 · cited 1×
“1) have been found to regulate cellular functions limited to distinct cell subsets that mediate autoimmunity, a finding of therapeutic relevance in human disease [9, 21].”
BackgroundSelf-citationMicroglia in Alzheimer's Disease: It's All About Context
Weitz, T. M., & Town, T. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/314185 · Cited by 95 · cited 1×
“In addition, an understanding of cellular markers and pathways that define these microglial populations is critical in identifying novel therapeutic targets in AD [17, 19, 20].”
BackgroundFormation and maintenance of Alzheimer’s disease beta-amyloid plaques in the absence of microglia
Grathwohl, S., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2010) · e-Neuroforum · doi:10.1515/nf-2010-0107 · Cited by 84
Blockade of Kv1.3 channels ameliorates radiation-induced brain injury
Peng, Y., Lu, K., Li, Z., Zhao, Y., Wang, Y., Hu, B., Xu, P., Shi, X., Zhou, B., Pennington, M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not221 · Cited by 78
Schilling, T., & Eder, C. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.07.008 · Cited by 76
Cytokine-dependent K+ channel profile of microglia at immunologically defined functional states
Fischer, H., Eder, C., Hadding, U., & Heinemann, U. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00398-o · Cited by 76
Upregulation of Kv1.3 K+channels in microglia deactivated by TGF-β
Schilling, T., Quandt, F. N., Cherny, V. V., Zhou, W., Heinemann, U., Decoursey, T. E., & Eder, C. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.4.c1123 · Cited by 73
Mullen, K. M., Rozycka, M., Rus, H., Hu, L., Cudrici, C., Zafranskaia, E., Pennington, M. W., Johns, D. C., Judge, S. I. V., & Calabresi, P. A. (2006) · Annals of Neurology · doi:10.1002/ana.20884 · Cited by 57
Menteyne, A., Levavasseur, F., Audinat, E., & Avignone, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006770 · Cited by 50
Lioudyno, M. I., Broccio, M., Sokolov, Y., Rasool, S., Wu, J., Alkire, M. T., Liu, V., Kozak, J. A., Dennison, P. R., Glabe, C. G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035090 · Cited by 45
Abnormal Gephyrin Immunoreactivity Associated With Alzheimer Disease Pathologic Changes
Hales, C. M., Rees, H. D., Seyfried, N. T., Dammer, E. B., Duong, D. M., Gearing, M., Montine, T. J., Troncoso, J. C., Thambisetty, M., Levey, A. I., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000435847.59828.db · Cited by 38
Self-citationThe Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials
Cornblath, D. R., Bienen, E. J., & Blight, A. R. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.03.007 · Cited by 37
HIV-1 Tat Protein Increases Microglial Outward K+ Current and Resultant Neurotoxic Activity
Liu, J., Xu, P., Collins, C., Liu, H., Zhang, J., Keblesh, J. P., & Xiong, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064904 · Cited by 28
Cited by
Hopperton, K. E., Mohammad, D., Trépanier, M. O., Giuliano, V, & Bazinet, R. P. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.246 · Cited by 622
Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
Self-citationNguyen, H. M., Grössinger, E. M., Horiuchi, M., Davis, K. W., Jin, L., Maezawa, I., & Wulff, H. (2017) · Glia · doi:10.1002/glia.23078 · Cited by 178
Self-citationLau, V., Ramer, L., & Tremblay, M.-È. (2023) · Nature Communications · doi:10.1038/s41467-023-37304-3 · Cited by 167
Rangaraju, S., Dammer, E. B., Raza, S. A., Gao, T., Xiao, H., Betarbet, R., Duong, D. M., Webster, J. A., Hales, C. M., Lah, J. J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0266-4 · Cited by 136
Self-citation
Metadata
- Authors
- Rangaraju, S., Gearing, M., Jin, L.-W., & Levey, A.
- Affiliations
- Emory University (US)
- University of California, Davis (US)
- Corresponding author
- Rangaraju, Srikant
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-02-06
- Volume
- 44
- Issue
- 3
- Pages
- 797-808
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC4402159
- OpenAlex
- W1718126001
- Cited by
- 137
- References
- 47
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 10 · 2023: 10 · 2022: 16 · 2021: 22 · 2020: 15 · 2019: 6 · 2018: 15 · 2017: 11 · 2016: 5 · 2015: 4
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Brain Foundation
- Emory University (P50AG025688, AG025688)
- Alzheimer's Disease Research Center, Emory University (P50 AG025688, AG025688)
- National Institute on Aging (P50AG025688)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Kv1.3 potassium channel, microglia
- MeSH terms
- Aged, Alzheimer Disease, Brain, Calcium-Binding Proteins, DNA-Binding Proteins, Female, Glial Fibrillary Acidic Protein, Humans, Male, Microfilament Proteins, Tubulin, Amyloid beta-Peptides, Microglia, Kv1.3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.